Seger Surgical Solutions

Seger Surgical Solutions is developing a laparoscopic bowel closure device to easily and quickly perform intracorporeal anastomosis.

Seger’s Novel Solution

Seger is developing Lap IA™, a laparoscopic bowel closure device to easily and quickly close and staple the common opening inside the body (intracorporeal) during anastomosis procedures. With Lap IA, surgeons can quickly and accurately align the edges of the bowel opening to easily close and staple the common opening.

The device works with a standard 12 millimeter trocar.

With Seger Surgical’s Lap IA closure device, surgeons can perform bowel anastomosis in a fully laparoscopic procedure for improved clinical results, fewer complications, and reduced healthcare costs.

  • Decreased pain
  • Smaller extraction incisions
  • Overall reduction in post op morbidity
  • Decreased length of stay (LOS, ~½-2 days shorter)
  • No bowel twisting, which eliminates the need for additional surgery

The Seger Opportunity

The Seger system allows surgeons to perform bowel resection in a fully laparoscopic procedure for improved clinical results, fewer complications, and reduced healthcare costs.

The Team

  • Kobby Greenberg, CEO: 15+ years’ experience in medical device industry; previous positions include CEO Cleanoscope, VP R&D Niti Surgical, mechanical design consultant for KG Holdings
  • Prof. Barry Salky, Co-Founder and Medical Director: Internationally recognized pioneer and key opinion leader in the laparoscopic surgery field; developed techniques now considered standard of practice; founder, Laparoscopic Surgery Division, Mount Sinai Hospital, NYC;  secretary of SAGES Foundation; past VP of SAGES; President of the International Federation of Surgical Endoscopic Societies (IFSES)
  • Leo R. Mindick, Co-Founder & Investor: Founder and CEO, Med-Tech Consultant Partners; years of experience in specialty medical devices, IP, regulatory, reimbursement; founder and former CEO multimillion-dollar specialty medical distribution company (later acquired)
  • David Hazzan, MD, Clinical Director: Chief, Department of Surgery B, Carmel Medical Center, Israel; responsible for preclinical and clinical trials

Trendlines’ directors: Yuval Almougy, Nitza Kardish

Scientific Advisory Board

Seger’s multinational advisory board comprises —

  • Ho-Seong Han, MD, PhD: Seoul National University Bundang Hospital, Korea
  • Antonio M. Lacy, MD: Hospital Clinic University of Barcelona, Spain
  • Armando Melani, MD: IRCAD, Rio de Janeiro, Brazil
  • Jungi Okuda, MD: Osaka Medical College, Japan
  • Alessio Pigazzi, MD, PhD: University of California, Irvine, United States
  • Natan Zundel, MD: Florida International University Herbert Wertheim College of Medicine, United States


Founded: December 2016
Technology development
Investor: The Trendlines Group
IP: 2 U.S. patents; 2 National phase

Background & Market

Bowel resection surgery involves removing all or part of the bowel (the intestine). Often, bowel resection is the result of colon cancer or gastric bypass surgery. Laparoscopic surgery is preferred clinically; yet, few procedures are performed 100% laparoscopically.

After resection is performed, the common opening of the two sections (of bowel) must be securely closed. Suturing the common opening by hand in a laparoscopic procedure is extremely complex and is only performed in 10% of cases. So, surgeons often perform anastomosis – connecting the two sections of bowel — outside the body (extracorporeal). The resected bowel is lifted and removed through an incision, the common bowel openings are stapled closed, the bowel is returned to its place in the body, and then the laparoscopic incision is closed.

The result of extracorporeal anastomosis: increased hospitalization costs due to increased post-operative complications and longer hospital stays.

According to Millenium Research Group, U.S. Market for Laparoscopic Devices 2013, the number of bowel resections is expected to exceed 980,000 in the United States and E.U. by 2020, with an annual growth of 10%, representing a $600 million market.

minimally invasive surgery
Laparascopic closure device for intracorporeal anastomosis


Kobby Greenberg, CEO
Seger Surgical logo

Font Resize